U.S. markets close in 5 hours 52 minutes

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.17000.0000 (0.00%)
As of 09:39AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close4.1700
Bid3.9400 x 900
Ask4.1700 x 1000
Day's Range4.0900 - 4.1700
52 Week Range0.5300 - 6.1000
Avg. Volume109,906
Market Cap85.247M
Beta (5Y Monthly)0.12
PE Ratio (TTM)N/A
EPS (TTM)-1.1500
Earnings DateApr 05, 2023 - Apr 20, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for RVPH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Reviva Pharmaceuticals Holdings
    Daily – Vickers Top Buyers & Sellers for 06/24/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Zacks Small Cap Research

    RVPH: Brilaroxazine Enthusiasm Abounds

    By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT March Update Since our previous report that was submitted on the occasion of Reviva Pharmaceutical Holdings, Inc’s (NASDAQ:RVPH) third quarter results, the company has reported the award of new patents, completed brilaroxazine drug-drug interaction studies and an updated stakeholders on the Phase III RECOVER trial. CEO

  • GlobeNewswire

    Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference

    CUPERTINO, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 35th Annual Roth Conference, taking place March 12-14 in

  • Simply Wall St.

    We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. Indeed, Reviva...